<P>R/D/E did not improve PFS compared with R/E. Because the PFS reported for R/E was similar to that reported for everolimus plus exemestane in patients with advanced breast cancer, it is possible that lower-dose ridaforolimus in the R/D/E arm (...
http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
https://www.riss.kr/link?id=A107738784
Rugo, Hope S. ; Tré ; dan, Olivier ; Ro, Jungsil ; Morales, Serafin M. ; Campone, Mario ; Musolino, Antonino ; Afonso, Noé ; mia ; Ferreira, Marta ; Park, Kyong Hwa ; Cortes, Javier ; Tan, Antoinette R. ; Blum, Joanne L. ; Eaton, Lamar ; Gause, Christine K. ; Wang, Zhen ; Im, Ellie ; Mauro, David J. ; Jones, Mary Beth ; Denker, Andrew ; Baselga, José
2017
-
SCOPUS,SCIE
학술저널
601-609(9쪽)
0
상세조회0
다운로드다국어 초록 (Multilingual Abstract)
<P>R/D/E did not improve PFS compared with R/E. Because the PFS reported for R/E was similar to that reported for everolimus plus exemestane in patients with advanced breast cancer, it is possible that lower-dose ridaforolimus in the R/D/E arm (...
<P>R/D/E did not improve PFS compared with R/E. Because the PFS reported for R/E was similar to that reported for everolimus plus exemestane in patients with advanced breast cancer, it is possible that lower-dose ridaforolimus in the R/D/E arm (from overlapping toxicities with IGF1R inhibitor) contributed to lack of improved PFS.</P>